Review





Similar Products

human cd160  (Sino Biological)
93
Sino Biological human cd160
Human Cd160, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd160/us12503516-670-73-75?v=Sino+Biological
Average 93 stars, based on 1 article reviews
human cd160 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
cd160 by55  (Miltenyi Biotec)
92
Miltenyi Biotec cd160 by55
Cd160 By55, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd160/pmc11662834-98-21-41?v=Miltenyi+Biotec
Average 92 stars, based on 1 article reviews
cd160 by55 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
3145003b anti human cd160  (fluidigm)
92
fluidigm 3145003b anti human cd160
3145003b Anti Human Cd160, supplied by fluidigm, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd160/pm41916320-679-97-95?v=fluidigm
Average 92 stars, based on 1 article reviews
3145003b anti human cd160 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
gene exp cd160 hs01073987 m1  (Thermo Fisher)
94
Thermo Fisher gene exp cd160 hs01073987 m1
The aberrant expression of BTLA , <t>CD160</t> , SPN , TIM3 , VISTA , TIGIT in CLL and psoriatic patients compared to HVs. ( a ) Higher expression of BTLA in in CLL patients, as well as Ps patients, compared to HVs (1500 vs. 5.372, p < 0.0001), (18.22 vs. 5.372, p < 0.0001). Higher expression of BTLA in CLL patients than psoriatic patients (1500 vs. 18.22, p < 0.0001). ( b ) Higher expression of CD160 in CLL patients than HVs (86.94 vs. 11.96, p < 0.0001). Higher expression of CD160 in psoriatic patients than HVs (48.92 vs. 11.96, p < 0.0001). Higher expression of CD160 in CLL than Ps patients (86.94 vs. 48.92, p = 0.0243). ( c ) Higher expression of SPN in CLL patients than HVs (1706 vs. 82.24, p < 0.0001). Higher expression of SPN in psoriatic patients than HVs (451.8 vs. 82.24, p < 0.0001). Higher expression of SPN expression in CLL patients than Ps patients (1706 vs. 451.8, p < 0.0001). ( d ) Lower expression of TIM-3 in Ps patients than HVs (0.02485 vs. 183.1, p < 0.0001). Higher expression of TIM-3 in CLL than Ps patients (226.9 vs. 0.02485, p < 0.0001). No difference in TIM-3 expression in CLL patients than HVs (226.9 vs. 183.1, p = 0.7251). ( e ) Higher expression of VISTA in Ps patients than HVs (196.7 vs. 34.93, p < 0.0001). Higher expression of VISTA in Ps patients compared to CLL patients (196.7 vs. 27.50, p < 0.0001). No difference in VISTA expression in CLL patients than HVs (27.50 vs. 34.93, p = 0.1854). ( f ) Higher expression of TIGIT in CLL patients than Ps patients (409.6 vs. 109.9, p < 0.0001). Higher expression of TIGIT in CLL patients than HVs (409.6 vs. 19.41, p < 0.0001). Higher expression of TIGIT in Ps patients than HVs (109.9 vs. 19.41, p < 0.0001). The bars spans from Q1 to Q3, and represents the interquartile range (IQR); a line marks the median.
Gene Exp Cd160 Hs01073987 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd160/pmc12249134-156-15-41?v=Thermo+Fisher
Average 94 stars, based on 1 article reviews
gene exp cd160 hs01073987 m1 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
gene exp cd160 hs00199894 m1  (Thermo Fisher)
85
Thermo Fisher gene exp cd160 hs00199894 m1
The aberrant expression of BTLA , <t>CD160</t> , SPN , TIM3 , VISTA , TIGIT in CLL and psoriatic patients compared to HVs. ( a ) Higher expression of BTLA in in CLL patients, as well as Ps patients, compared to HVs (1500 vs. 5.372, p < 0.0001), (18.22 vs. 5.372, p < 0.0001). Higher expression of BTLA in CLL patients than psoriatic patients (1500 vs. 18.22, p < 0.0001). ( b ) Higher expression of CD160 in CLL patients than HVs (86.94 vs. 11.96, p < 0.0001). Higher expression of CD160 in psoriatic patients than HVs (48.92 vs. 11.96, p < 0.0001). Higher expression of CD160 in CLL than Ps patients (86.94 vs. 48.92, p = 0.0243). ( c ) Higher expression of SPN in CLL patients than HVs (1706 vs. 82.24, p < 0.0001). Higher expression of SPN in psoriatic patients than HVs (451.8 vs. 82.24, p < 0.0001). Higher expression of SPN expression in CLL patients than Ps patients (1706 vs. 451.8, p < 0.0001). ( d ) Lower expression of TIM-3 in Ps patients than HVs (0.02485 vs. 183.1, p < 0.0001). Higher expression of TIM-3 in CLL than Ps patients (226.9 vs. 0.02485, p < 0.0001). No difference in TIM-3 expression in CLL patients than HVs (226.9 vs. 183.1, p = 0.7251). ( e ) Higher expression of VISTA in Ps patients than HVs (196.7 vs. 34.93, p < 0.0001). Higher expression of VISTA in Ps patients compared to CLL patients (196.7 vs. 27.50, p < 0.0001). No difference in VISTA expression in CLL patients than HVs (27.50 vs. 34.93, p = 0.1854). ( f ) Higher expression of TIGIT in CLL patients than Ps patients (409.6 vs. 109.9, p < 0.0001). Higher expression of TIGIT in CLL patients than HVs (409.6 vs. 19.41, p < 0.0001). Higher expression of TIGIT in Ps patients than HVs (109.9 vs. 19.41, p < 0.0001). The bars spans from Q1 to Q3, and represents the interquartile range (IQR); a line marks the median.
Gene Exp Cd160 Hs00199894 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd160/us12312582-296-27--1?v=Thermo+Fisher
Average 85 stars, based on 1 article reviews
gene exp cd160 hs00199894 m1 - by Bioz Stars, 2026-08
85/100 stars
  Buy from Supplier
anti-human cd160 (by55)  (Thermo Fisher)
90
Thermo Fisher anti-human cd160 (by55)
The aberrant expression of BTLA , <t>CD160</t> , SPN , TIM3 , VISTA , TIGIT in CLL and psoriatic patients compared to HVs. ( a ) Higher expression of BTLA in in CLL patients, as well as Ps patients, compared to HVs (1500 vs. 5.372, p < 0.0001), (18.22 vs. 5.372, p < 0.0001). Higher expression of BTLA in CLL patients than psoriatic patients (1500 vs. 18.22, p < 0.0001). ( b ) Higher expression of CD160 in CLL patients than HVs (86.94 vs. 11.96, p < 0.0001). Higher expression of CD160 in psoriatic patients than HVs (48.92 vs. 11.96, p < 0.0001). Higher expression of CD160 in CLL than Ps patients (86.94 vs. 48.92, p = 0.0243). ( c ) Higher expression of SPN in CLL patients than HVs (1706 vs. 82.24, p < 0.0001). Higher expression of SPN in psoriatic patients than HVs (451.8 vs. 82.24, p < 0.0001). Higher expression of SPN expression in CLL patients than Ps patients (1706 vs. 451.8, p < 0.0001). ( d ) Lower expression of TIM-3 in Ps patients than HVs (0.02485 vs. 183.1, p < 0.0001). Higher expression of TIM-3 in CLL than Ps patients (226.9 vs. 0.02485, p < 0.0001). No difference in TIM-3 expression in CLL patients than HVs (226.9 vs. 183.1, p = 0.7251). ( e ) Higher expression of VISTA in Ps patients than HVs (196.7 vs. 34.93, p < 0.0001). Higher expression of VISTA in Ps patients compared to CLL patients (196.7 vs. 27.50, p < 0.0001). No difference in VISTA expression in CLL patients than HVs (27.50 vs. 34.93, p = 0.1854). ( f ) Higher expression of TIGIT in CLL patients than Ps patients (409.6 vs. 109.9, p < 0.0001). Higher expression of TIGIT in CLL patients than HVs (409.6 vs. 19.41, p < 0.0001). Higher expression of TIGIT in Ps patients than HVs (109.9 vs. 19.41, p < 0.0001). The bars spans from Q1 to Q3, and represents the interquartile range (IQR); a line marks the median.
Anti Human Cd160 (By55), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd160/pm39269653-89-27-43?v=Thermo+Fisher
Average 90 stars, based on 1 article reviews
anti-human cd160 (by55) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
anti cd160  (OriGene)
92
OriGene anti cd160
The aberrant expression of BTLA , <t>CD160</t> , SPN , TIM3 , VISTA , TIGIT in CLL and psoriatic patients compared to HVs. ( a ) Higher expression of BTLA in in CLL patients, as well as Ps patients, compared to HVs (1500 vs. 5.372, p < 0.0001), (18.22 vs. 5.372, p < 0.0001). Higher expression of BTLA in CLL patients than psoriatic patients (1500 vs. 18.22, p < 0.0001). ( b ) Higher expression of CD160 in CLL patients than HVs (86.94 vs. 11.96, p < 0.0001). Higher expression of CD160 in psoriatic patients than HVs (48.92 vs. 11.96, p < 0.0001). Higher expression of CD160 in CLL than Ps patients (86.94 vs. 48.92, p = 0.0243). ( c ) Higher expression of SPN in CLL patients than HVs (1706 vs. 82.24, p < 0.0001). Higher expression of SPN in psoriatic patients than HVs (451.8 vs. 82.24, p < 0.0001). Higher expression of SPN expression in CLL patients than Ps patients (1706 vs. 451.8, p < 0.0001). ( d ) Lower expression of TIM-3 in Ps patients than HVs (0.02485 vs. 183.1, p < 0.0001). Higher expression of TIM-3 in CLL than Ps patients (226.9 vs. 0.02485, p < 0.0001). No difference in TIM-3 expression in CLL patients than HVs (226.9 vs. 183.1, p = 0.7251). ( e ) Higher expression of VISTA in Ps patients than HVs (196.7 vs. 34.93, p < 0.0001). Higher expression of VISTA in Ps patients compared to CLL patients (196.7 vs. 27.50, p < 0.0001). No difference in VISTA expression in CLL patients than HVs (27.50 vs. 34.93, p = 0.1854). ( f ) Higher expression of TIGIT in CLL patients than Ps patients (409.6 vs. 109.9, p < 0.0001). Higher expression of TIGIT in CLL patients than HVs (409.6 vs. 19.41, p < 0.0001). Higher expression of TIGIT in Ps patients than HVs (109.9 vs. 19.41, p < 0.0001). The bars spans from Q1 to Q3, and represents the interquartile range (IQR); a line marks the median.
Anti Cd160, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd160/pmc11487165-427-22-24?v=OriGene
Average 92 stars, based on 1 article reviews
anti cd160 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
cd160 pe antibody  (Thermo Fisher)
90
Thermo Fisher cd160 pe antibody
The aberrant expression of BTLA , <t>CD160</t> , SPN , TIM3 , VISTA , TIGIT in CLL and psoriatic patients compared to HVs. ( a ) Higher expression of BTLA in in CLL patients, as well as Ps patients, compared to HVs (1500 vs. 5.372, p < 0.0001), (18.22 vs. 5.372, p < 0.0001). Higher expression of BTLA in CLL patients than psoriatic patients (1500 vs. 18.22, p < 0.0001). ( b ) Higher expression of CD160 in CLL patients than HVs (86.94 vs. 11.96, p < 0.0001). Higher expression of CD160 in psoriatic patients than HVs (48.92 vs. 11.96, p < 0.0001). Higher expression of CD160 in CLL than Ps patients (86.94 vs. 48.92, p = 0.0243). ( c ) Higher expression of SPN in CLL patients than HVs (1706 vs. 82.24, p < 0.0001). Higher expression of SPN in psoriatic patients than HVs (451.8 vs. 82.24, p < 0.0001). Higher expression of SPN expression in CLL patients than Ps patients (1706 vs. 451.8, p < 0.0001). ( d ) Lower expression of TIM-3 in Ps patients than HVs (0.02485 vs. 183.1, p < 0.0001). Higher expression of TIM-3 in CLL than Ps patients (226.9 vs. 0.02485, p < 0.0001). No difference in TIM-3 expression in CLL patients than HVs (226.9 vs. 183.1, p = 0.7251). ( e ) Higher expression of VISTA in Ps patients than HVs (196.7 vs. 34.93, p < 0.0001). Higher expression of VISTA in Ps patients compared to CLL patients (196.7 vs. 27.50, p < 0.0001). No difference in VISTA expression in CLL patients than HVs (27.50 vs. 34.93, p = 0.1854). ( f ) Higher expression of TIGIT in CLL patients than Ps patients (409.6 vs. 109.9, p < 0.0001). Higher expression of TIGIT in CLL patients than HVs (409.6 vs. 19.41, p < 0.0001). Higher expression of TIGIT in Ps patients than HVs (109.9 vs. 19.41, p < 0.0001). The bars spans from Q1 to Q3, and represents the interquartile range (IQR); a line marks the median.
Cd160 Pe Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd160/pmc11709102__ACEL___24___e14351___s001-15-163-165?v=Thermo+Fisher
Average 90 stars, based on 1 article reviews
cd160 pe antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


The aberrant expression of BTLA , CD160 , SPN , TIM3 , VISTA , TIGIT in CLL and psoriatic patients compared to HVs. ( a ) Higher expression of BTLA in in CLL patients, as well as Ps patients, compared to HVs (1500 vs. 5.372, p < 0.0001), (18.22 vs. 5.372, p < 0.0001). Higher expression of BTLA in CLL patients than psoriatic patients (1500 vs. 18.22, p < 0.0001). ( b ) Higher expression of CD160 in CLL patients than HVs (86.94 vs. 11.96, p < 0.0001). Higher expression of CD160 in psoriatic patients than HVs (48.92 vs. 11.96, p < 0.0001). Higher expression of CD160 in CLL than Ps patients (86.94 vs. 48.92, p = 0.0243). ( c ) Higher expression of SPN in CLL patients than HVs (1706 vs. 82.24, p < 0.0001). Higher expression of SPN in psoriatic patients than HVs (451.8 vs. 82.24, p < 0.0001). Higher expression of SPN expression in CLL patients than Ps patients (1706 vs. 451.8, p < 0.0001). ( d ) Lower expression of TIM-3 in Ps patients than HVs (0.02485 vs. 183.1, p < 0.0001). Higher expression of TIM-3 in CLL than Ps patients (226.9 vs. 0.02485, p < 0.0001). No difference in TIM-3 expression in CLL patients than HVs (226.9 vs. 183.1, p = 0.7251). ( e ) Higher expression of VISTA in Ps patients than HVs (196.7 vs. 34.93, p < 0.0001). Higher expression of VISTA in Ps patients compared to CLL patients (196.7 vs. 27.50, p < 0.0001). No difference in VISTA expression in CLL patients than HVs (27.50 vs. 34.93, p = 0.1854). ( f ) Higher expression of TIGIT in CLL patients than Ps patients (409.6 vs. 109.9, p < 0.0001). Higher expression of TIGIT in CLL patients than HVs (409.6 vs. 19.41, p < 0.0001). Higher expression of TIGIT in Ps patients than HVs (109.9 vs. 19.41, p < 0.0001). The bars spans from Q1 to Q3, and represents the interquartile range (IQR); a line marks the median.

Journal: Cancers

Article Title: Aberrant Expression of BTLA , CD160 , SPN , TIM-3 , VISTA and TIGIT in Chronic Lymphocytic Leukemia and Psoriasis Patients Compared to Healthy Volunteers

doi: 10.3390/cancers17132116

Figure Lengend Snippet: The aberrant expression of BTLA , CD160 , SPN , TIM3 , VISTA , TIGIT in CLL and psoriatic patients compared to HVs. ( a ) Higher expression of BTLA in in CLL patients, as well as Ps patients, compared to HVs (1500 vs. 5.372, p < 0.0001), (18.22 vs. 5.372, p < 0.0001). Higher expression of BTLA in CLL patients than psoriatic patients (1500 vs. 18.22, p < 0.0001). ( b ) Higher expression of CD160 in CLL patients than HVs (86.94 vs. 11.96, p < 0.0001). Higher expression of CD160 in psoriatic patients than HVs (48.92 vs. 11.96, p < 0.0001). Higher expression of CD160 in CLL than Ps patients (86.94 vs. 48.92, p = 0.0243). ( c ) Higher expression of SPN in CLL patients than HVs (1706 vs. 82.24, p < 0.0001). Higher expression of SPN in psoriatic patients than HVs (451.8 vs. 82.24, p < 0.0001). Higher expression of SPN expression in CLL patients than Ps patients (1706 vs. 451.8, p < 0.0001). ( d ) Lower expression of TIM-3 in Ps patients than HVs (0.02485 vs. 183.1, p < 0.0001). Higher expression of TIM-3 in CLL than Ps patients (226.9 vs. 0.02485, p < 0.0001). No difference in TIM-3 expression in CLL patients than HVs (226.9 vs. 183.1, p = 0.7251). ( e ) Higher expression of VISTA in Ps patients than HVs (196.7 vs. 34.93, p < 0.0001). Higher expression of VISTA in Ps patients compared to CLL patients (196.7 vs. 27.50, p < 0.0001). No difference in VISTA expression in CLL patients than HVs (27.50 vs. 34.93, p = 0.1854). ( f ) Higher expression of TIGIT in CLL patients than Ps patients (409.6 vs. 109.9, p < 0.0001). Higher expression of TIGIT in CLL patients than HVs (409.6 vs. 19.41, p < 0.0001). Higher expression of TIGIT in Ps patients than HVs (109.9 vs. 19.41, p < 0.0001). The bars spans from Q1 to Q3, and represents the interquartile range (IQR); a line marks the median.

Article Snippet: cDNA was used in a qRT-PCR to measure the mRNA expression of BTLA (Hs00699198_m1), CD160 (Hs01073987_m1), SPN (CD43; Hs01872322_s1), TIM-3 ( HAVCR2 ; Hs00262170_m1), VISTA ( C10orf54 ; Hs00735289_m1) and TIGIT (Hs00545087_m1) with the use of the TaqMan Gene Expression Assay (Applied Biosystems, Foster City, CA, USA), as well as the 7500 Fast Dx Real-Time PCR Instrument (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s instructions.

Techniques: Expressing

Positive correlations between expression of BTLA , CD160 , SPN , TIM3 , VISTA , and TIGIT in CLL. The results are presented as the log10 value of 2 −∆∆Ct , with the regression line marked. ( a ) Strong correlation between the expressions of SPN and CD160 (r = 0.7822, p < 0.0001). ( b ) Strong correlation between the expressions of SPN and BTLA (r = 0.7960, p < 0.0001). ( c ) Moderate correlation between the expressions of SPN and TIGIT (r = 0.6800, p < 0.0001). ( d ) Moderate correlation between the expressions of CD160 and TIM3 (r = 0.6212, p < 0.0001). ( e ) Moderate correlation between the expressions of BTLA and TIGIT (r = 0.6774, p < 0.0001). ( f ) Moderate correlation between the expressions of TIM3 and VISTA (r = 0.6331, p < 0.0001).

Journal: Cancers

Article Title: Aberrant Expression of BTLA , CD160 , SPN , TIM-3 , VISTA and TIGIT in Chronic Lymphocytic Leukemia and Psoriasis Patients Compared to Healthy Volunteers

doi: 10.3390/cancers17132116

Figure Lengend Snippet: Positive correlations between expression of BTLA , CD160 , SPN , TIM3 , VISTA , and TIGIT in CLL. The results are presented as the log10 value of 2 −∆∆Ct , with the regression line marked. ( a ) Strong correlation between the expressions of SPN and CD160 (r = 0.7822, p < 0.0001). ( b ) Strong correlation between the expressions of SPN and BTLA (r = 0.7960, p < 0.0001). ( c ) Moderate correlation between the expressions of SPN and TIGIT (r = 0.6800, p < 0.0001). ( d ) Moderate correlation between the expressions of CD160 and TIM3 (r = 0.6212, p < 0.0001). ( e ) Moderate correlation between the expressions of BTLA and TIGIT (r = 0.6774, p < 0.0001). ( f ) Moderate correlation between the expressions of TIM3 and VISTA (r = 0.6331, p < 0.0001).

Article Snippet: cDNA was used in a qRT-PCR to measure the mRNA expression of BTLA (Hs00699198_m1), CD160 (Hs01073987_m1), SPN (CD43; Hs01872322_s1), TIM-3 ( HAVCR2 ; Hs00262170_m1), VISTA ( C10orf54 ; Hs00735289_m1) and TIGIT (Hs00545087_m1) with the use of the TaqMan Gene Expression Assay (Applied Biosystems, Foster City, CA, USA), as well as the 7500 Fast Dx Real-Time PCR Instrument (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s instructions.

Techniques: Expressing

Positive correlations between expression of BTLA , CD160 , SPN , TIM3 , VISTA , TIGIT in Ps. The results are presented as the log10 value of 2 −∆∆Ct , with the regression line marked. ( a ) Strong correlation between the expressions of SPN and TIGIT (r = 0.8246, p < 0.0001). ( b ) Moderate correlation between the expressions of SPN and TIM3 (r = 0.6572, p < 0.0001). ( c ) Strong correlation between the expressions of SPN and BTLA (r = 0.7016, p < 0.0001). ( d ) Strong correlation between the expressions of SPN and CD160 (r = 0.7183, p < 0.0001). ( e ) Moderate correlation between the expressions of CD160 and TIM3 (r = 0.6263, p < 0.0001). ( f ) Strong correlation between the expressions of CD160 and TIGIT (r = 0.7576, p < 0.0001).

Journal: Cancers

Article Title: Aberrant Expression of BTLA , CD160 , SPN , TIM-3 , VISTA and TIGIT in Chronic Lymphocytic Leukemia and Psoriasis Patients Compared to Healthy Volunteers

doi: 10.3390/cancers17132116

Figure Lengend Snippet: Positive correlations between expression of BTLA , CD160 , SPN , TIM3 , VISTA , TIGIT in Ps. The results are presented as the log10 value of 2 −∆∆Ct , with the regression line marked. ( a ) Strong correlation between the expressions of SPN and TIGIT (r = 0.8246, p < 0.0001). ( b ) Moderate correlation between the expressions of SPN and TIM3 (r = 0.6572, p < 0.0001). ( c ) Strong correlation between the expressions of SPN and BTLA (r = 0.7016, p < 0.0001). ( d ) Strong correlation between the expressions of SPN and CD160 (r = 0.7183, p < 0.0001). ( e ) Moderate correlation between the expressions of CD160 and TIM3 (r = 0.6263, p < 0.0001). ( f ) Strong correlation between the expressions of CD160 and TIGIT (r = 0.7576, p < 0.0001).

Article Snippet: cDNA was used in a qRT-PCR to measure the mRNA expression of BTLA (Hs00699198_m1), CD160 (Hs01073987_m1), SPN (CD43; Hs01872322_s1), TIM-3 ( HAVCR2 ; Hs00262170_m1), VISTA ( C10orf54 ; Hs00735289_m1) and TIGIT (Hs00545087_m1) with the use of the TaqMan Gene Expression Assay (Applied Biosystems, Foster City, CA, USA), as well as the 7500 Fast Dx Real-Time PCR Instrument (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s instructions.

Techniques: Expressing